Reference | Anti-TNFα agent | Trial name | Enrolment start date | Comparator | N | Patient population |
---|---|---|---|---|---|---|
Elliott et al 199416 | Infliximab | NA | 1993 | Placebo | 72 | MTX experienced |
Moreland et al 199717 | Etanercept | NA | – | Placebo | 180 | MTX experienced |
Maini et al 199818 | Infliximab | NA | 1994 | Placebo | 101 | MTX experienced |
Maini et al 199919 | Infliximab | ATTRACT | 1997 | Placebo | 428 | MTX experienced |
Moreland et al 199920 | Etanercept | NA | – | Placebo | 234 | MTX experienced |
Weinblatt et al 199921 | Etanercept | NA | – | MTX | 89 | MTX experienced |
Bathon et al 200022 | Etanercept | ERA | 1997 | MTX | 632 | MTX naive |
Kavanaugh et al 200023 | Infliximab | NA | 1995 | Placebo | 28 | MTX experienced |
Choy et al 200224 | Certolizumab | NA | – | Placebo | 36 | MTX experienced |
Furst et al 200325 | Adalimumab | STAR | 2000 | Placebo | 636 | MTX experienced |
van de Putte et al 200326 | Adalimumab | DE007 | 2001 | Placebo | 284 | MTX experienced |
Weinblatt et al 200327 | Adalimumab | ARMADA | – | MTX | 271 | MTX experienced |
Keystone et al 200428 | Adalimumab | DE019 | 2002 | MTX | 619 | MTX experienced |
van de Putte et al 200429 | Adalimumab | DE011 | 2000 | Placebo | 544 | MTX experienced |
Genovese et al 200430 | Etanercept | NA | – | Anakinra | 244 | MTX experienced |
Keystone et al 200431 | Etanercept | NA | – | Placebo | 420 | MTX experienced |
Klareskog et al 200432 | Etanercept | TEMPO | 2000 | MTX | 652 | MTX experienced |
Lan et al 200433 | Etanercept | NA | 2000 | Placebo | 58 | MTX experienced |
St. Clair et al 200434 | Infliximab | ASPIRE | 2000 | MTX | 1004 | MTX naive |
Johnsen et al 200635 | Etanercept | NA | 1999 | Etanercept | 77 | MTX experienced |
Abe et al 200636 | Infliximab | NA | 2000 | Placebo | 147 | MTX experienced |
Leirisalo-Repo et al 200637 | Infliximab | NEO-RACO | 2005 | Placebo | 99 | MTX experienced |
Westhovens et al 200638 | Infliximab | START | 2001 | Placebo | 1082 | MTX experienced |
Zhang et al 200639 | Infliximab | NA | 2003 | Placebo | 173 | MTX experienced |
Breedveld et al 200640 | Adalimumab | PREMIER | 2001 | MTX | 799 | MTX naive |
Kim et al 200741 | Adalimumab | NA | 2003 | MTX | 128 | MTX experienced |
Weisman et al 200742 | Etanercept | NA | 2000 | Placebo | 535 | MTX experienced |
Zhou et al 200743 | Golimumab | NA | 2001 | Placebo | 36 | MTX experienced |
Durez et al 200744 | Infliximab | NA | 2003 | MTX and prednisone | 44 | MTX naive |
Fleischmann et al 200845* | Certolizumab | FAST4WARD | 2003 | Placebo | 220 | MTX experienced |
Keystone et al 200846 | Certolizumab | RAPID1 | 2005 | MTX | 982 | MTX experienced |
Smolen et al 200847* | Certolizumab | RAPID2 | 2005 | MTX | 619 | MTX experienced |
Combe et al 200848* | Etanercept | 309 | 2000 | SSZ | 254 | MTX experienced |
Emery et al 200849 | Etanercept | COMET | 2004 | MTX | 542 | MTX naive |
Kameda et al 200850 | Etanercept | JESMR | 2005 | MTX | 151 | MTX experienced |
Sheehy et al 200851 | Etanercept | NA | – | MTX | 40 | MTX naive |
Wyeth data on file | Etanercept | 0881A1-319 | 2006 | MTX | 156 | MTX experienced |
Sennels et al 200852 | Etanercept | ADORE | 2003 | Etanercept | 25 | MTX experienced |
Weinblatt et al 200853 | Etanercept | NA | 2005 | Etanercept | 200 | MTX experienced |
Miyasaka et al 200854 | Adalimumab | CHANGE | 2004 | Placebo | 352 | MTX experienced |
Kay et al 200855 | Golimumab | NA | 2003 | MTX | 172 | MTX experienced |
Keystone 200814 | Golimumab | GO–FORWARD | 2005 | MTX | 444 | MTX experienced |
Emery et al 200915 | Golimumab | GO–BEFORE | 2005 | MTX | 634 | MTX naive |
Smolen et al 200956 | Golimumab | GO–AFTER | 2006 | Placebo | 461 | MTX experienced |
MTX, methotrexate; NA, not available; TNF, tumour necrosis factor.
↵* Date denotes the first date of publication (online)